W
William C. Hahn
Researcher at Harvard University
Publications - 515
Citations - 85047
William C. Hahn is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 130, co-authored 448 publications receiving 72191 citations. Previous affiliations of William C. Hahn include Brigham and Women's Hospital & University of Washington.
Papers
More filters
Journal ArticleDOI
Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers
Joseph Rosenbluh,Joseph Rosenbluh,Johnathan Mercer,Johnathan Mercer,Yashaswi Shrestha,Rachel A. Oliver,Rachel A. Oliver,Pablo Tamayo,John G. Doench,Itay Tirosh,Federica Piccioni,Ella Hartenian,Heiko Horn,Heiko Horn,Lola Fagbami,David E. Root,Jacob D. Jaffe,Kasper Lage,Kasper Lage,Jesse S. Boehm,William C. Hahn,William C. Hahn +21 more
TL;DR: These studies identify previously unreported regulators of β-catenin, define functional networks required for the survival ofβ- catenin-active cancers, and provide an experimental strategy that may be applied to define other signaling networks.
Journal ArticleDOI
Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges
TL;DR: The current state of cancer genome analysis is reviewed and the challenges and opportunities necessary to implement these technologies in a clinical setting are discussed.
Journal ArticleDOI
BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma
Joseph H. Jeong,Zhenxiong Wang,Alexander S. Guimaraes,Xuesong Ouyang,Jose L. Figueiredo,Zhihu Ding,Shan Jiang,Isil Guney,Isil Guney,Gyeong Hoon Kang,Eyoung Shin,William C. Hahn,William C. Hahn,Massimo Loda,Massimo Loda,Cory Abate-Shen,Ralph Weissleder,Lynda Chin +17 more
TL;DR: A genetically-engineered mouse model of invasive prostate cancers, whereby an activating mutation of BRAFV600E was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency provides genetic proof that activation of MAP kinase signaling is sufficient to drive prostate tumorigenesis.
Journal ArticleDOI
Integrated genetic and pharmacologic interrogation of rare cancers
Andrew L. Hong,Andrew L. Hong,Andrew L. Hong,Yuen-Yi Tseng,Glenn S. Cowley,Oliver Jonas,Jaime H. Cheah,Bryan D. Kynnap,Mihir B. Doshi,Mihir B. Doshi,Coyin Oh,Stephanie C. Meyer,Stephanie C. Meyer,Alanna J. Church,Shubhroz Gill,Craig M. Bielski,Paula Keskula,Alma Imamovic,Alma Imamovic,Sara Howell,Gregory V. Kryukov,Gregory V. Kryukov,Paul A. Clemons,Aviad Tsherniak,Francisca Vazquez,Brian D. Crompton,Brian D. Crompton,Alykhan F. Shamji,Carlos Rodriguez-Galindo,Carlos Rodriguez-Galindo,Carlos Rodriguez-Galindo,Katherine A. Janeway,Katherine A. Janeway,Charles W. M. Roberts,Charles W. M. Roberts,Charles W. M. Roberts,Kimberly Stegmaier,Kimberly Stegmaier,Kimberly Stegmaier,Paul Van Hummelen,Michael J. Cima,Robert Langer,Levi A. Garraway,Stuart L. Schreiber,Stuart L. Schreiber,David E. Root,William C. Hahn,William C. Hahn,William C. Hahn,Jesse S. Boehm +49 more
TL;DR: In this article, the authors developed a patient-derived cancer cell line, CLF-PED-015-T, from a paediatric patient with a rare undifferentiated sarcoma.
Proceedings ArticleDOI
Abstract LB-126: ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming,Xiaofeng Wang,Boris G. Wilson,Francisca Vazquez,Jeffrey R. Haswell,Haley E. Manchester,Youngha Kim,Gregory V. Kryukov,Mahmoud Ghandi,Andrew J. Aguirre,Zainab Jagani,Zhong Wang,Levi A. Garraway,William C. Hahn,Charles W. M. Roberts +14 more
TL;DR: It is demonstrated that cancer cell lines harboring mutations in ARID1A are specifically dependent upon ARIDs1B and insight is provided into the structural role of ARid1A/B in the SWI/SNF chromatin remodeling complex.